Bubbles and Biomarkers: A Cautionary Tale

by

It has come to our attention – and, frankly, it’s hard to ignore when the scribes at the Guild of Alchemists and Venture Capitalists start chattering – that Boxer Capital Management, LLC, a firm whose name suggests a rather optimistic view of conflict resolution, has recently acquired a substantial holding in Celcuity. One hundred and thirty-five thousand shares, to be precise. A sum that, when translated from the arcane language of quarterly averages, amounts to approximately eleven million gold pieces1. A significant investment, certainly. But is it wise? That, dear reader, is a question best pondered whilst sipping something strong and bracing.

What Happened (Or, The Numbers Tell a Story…Sort Of)

According to a filing with the Regulatory Scribes (formerly known as the SEC, but they’ve had a rebranding), Boxer Capital has increased its stake in Celcuity. This occurred during the fourth quarter of 2025, a period noted for unusually high levels of optimism, a scarcity of common sense, and a disturbing fondness for hats shaped like pineapples. The transaction is valued at eleven million gold pieces, based on the average closing price. As of December 31st, 2025, the position was worth twenty-two million and forty-four thousand gold pieces, a rise of eighteen million gold pieces, due to both the aforementioned trading activity and, let’s be honest, a healthy dose of speculative froth. It’s a bit like watching a particularly enthusiastic balloon inflate. One wonders when, not if, it will pop.

What Else to Know (Or, The Shape of the Portfolio)

This Celcuity investment now represents 4.9% of Boxer Capital’s 13F reportable assets. Which is a perfectly respectable number, assuming one believes in respectable numbers. Their top holdings, as of the last accounting, are as follows:

  • NASDAQ:TNGX: 96.36 million gold pieces (21.1% of AUM)
  • NASDAQ:RVMD: 31.86 million gold pieces (7.0% of AUM)
  • NASDAQ:KOD: 31.76 million gold pieces (7.0% of AUM)
  • NASDAQ:KYMR: 25.61 million gold pieces (5.6% of AUM)
  • NASDAQ: CELC: 22.44 million gold pieces (4.9% of AUM)

As of February 17th, 2026, Celcuity shares were priced at 107.32 gold pieces, a staggering 741.1% increase over the past year. They’ve, shall we say, outperformed the Standard & Poor’s 500 by a rather embarrassing 721.3 percentage points. One suspects the S&P 500 is feeling rather glum about this. It’s all very well being a benchmark, but it’s no fun if everyone else is having a party and you’re stuck polishing the silverware.

Company Overview (Or, What They Claim to Do)

Metric Value
Price (as of market close February 17, 2026) 107.32 gold pieces
Market capitalization 4.97 billion gold pieces
Net income (TTM) (162.72 million gold pieces)
One-year price change 741.1%

Company Snapshot (Or, The Story They’re Selling)

  • Celcuity develops molecularly targeted therapies for cancer, with key products including the CELsignia diagnostic platform and the investigational drug Gedatolisib for breast cancer treatment.2
  • The company operates a clinical-stage biotechnology business model, generating value through the development and potential commercialization of proprietary diagnostics and therapeutics, with future revenue expected from product approvals and partnerships.
  • Primary customers are healthcare providers and oncologists treating patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer in the United States.

Celcuity, you see, is a clinical-stage biotechnology company focused on precision oncology, leveraging its proprietary CELsignia platform to identify abnormal cellular signaling in cancer cells and guide targeted therapy development. It’s all very clever, and one assumes the scientists involved are exceptionally bright. But it’s also, let’s be frank, a gamble. A very expensive gamble.

Their competitive advantage, they claim, lies in their integrated approach to diagnostics and therapeutics, underpinned by partnerships such as their license agreement with Pfizer for Gedatolisib. One hopes Pfizer has a good lawyer. And a very large escape clause.

What This Transaction Means for Investors (Or, A Word to the Wise)

Boxer Capital, a California-based investment firm, recently disclosed the acquisition of more than 135,000 shares of Celcuity, a biotech stock. Here are some key takeaways for investors. Though, one suspects, most investors are too busy chasing the next shiny object to pay attention.

First, Celcuity is now Boxer Capital’s fifth-largest position, with 225,000 shares owned, valued at a total of 22.44 million gold pieces. A substantial commitment, to be sure. But is it a sensible commitment? That remains to be seen.

Second, while this is an aggressive—and bullish—move by Boxer Capital, it’s not one that should be blindly copied by all, or even most, retail investors. Here’s why. Because, frankly, most retail investors have the financial acumen of a startled badger.

Celcuity is a biotech stock. That means the company is engaged in the process of developing treatments for disease. Specifically, cancer. This work is high-risk and high-reward. Biotech companies tend to invest heavily in research and development. If their treatments are effective and receive approval from government oversight panels, they can produce enormous profits, leading to soaring stock prices. On the other hand, disappointing clinical trial data or failing to secure government approval can lead to a tumbling stock price. It’s a bit like playing a game of dice with your life savings.

In other words, this sector is volatile—meaning it’s not for every investor. Indeed, even aggressive investors may be wise to spread their risk through a biotech ETF, rather than put all their eggs in one basket. Or, you know, just invest in something boring and reliable, like turnips.

1 Gold pieces are used here as a unit of account for dramatic effect and to avoid the vulgarity of decimal places.
2 The CELsignia platform, we are told, uses “proprietary algorithms” and “advanced data analytics.” One suspects it involves a lot of blinking lights and a very enthusiastic intern.

Read More

2026-03-06 17:22